The therapy, haploidentical bone marrow transplant with thiotepa and posttransplant cyclophosphamide, is as safe and more affordable than the recently FDA-approved myeloablative gene therapy and gene editing treatments.

This new entry to the field works in the background to provide real-time risk assessments, with no manual inputs from health care providers required.

The authors hope the report will provide insight on the importance of education, screening and awareness to all health care providers.

A prospective cohort of veterans including those with military toxic exposures, such as burn pits, will be screened annually with low-dose chest CT to detect lung cancer and other disease early.

Cathy Eng, MD, will participate in a congressional briefing on April 15 focused on “Addressing Representation in Clinical Trials.”

While immune checkpoint inhibitors that target the PD-1 molecule on T-cells have proven to be effective with many cancers, these immunotherapies have not worked for acute myeloid leukemia (AML), but new research has identified a “cousin” molecule as a potential therapeutic target for AML. 

The Food and Drug Administration first granted marketing approval for the DigniCap system for patients with breast cancer in 2015, then in 2017 the FDA expanded the authorization, making it the first cooling cap cleared for use in cancer patients with solid tumors, such as breast cancer, ovarian cancer and colorectal cancer.